← All trials
NCT04510220
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Aug 12, 2020
- Last posted
- Aug 12, 2020
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- NovartisCollaborator
- Harvard UniversityOfficial
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.